MA54542A - Compositions de sparsentan amorphe - Google Patents
Compositions de sparsentan amorpheInfo
- Publication number
- MA54542A MA54542A MA054542A MA54542A MA54542A MA 54542 A MA54542 A MA 54542A MA 054542 A MA054542 A MA 054542A MA 54542 A MA54542 A MA 54542A MA 54542 A MA54542 A MA 54542A
- Authority
- MA
- Morocco
- Prior art keywords
- sparsentan
- amorphous
- compositions
- sparsentan compositions
- amorphous sparsentan
- Prior art date
Links
- WRFHGDPIDHPWIQ-UHFFFAOYSA-N 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide Chemical compound O=C1N(CC=2C=C(COCC)C(=CC=2)C=2C(=CC=CC=2)S(=O)(=O)NC=2C(=C(C)ON=2)C)C(CCCC)=NC21CCCC2 WRFHGDPIDHPWIQ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 229950002009 sparsentan Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862783947P | 2018-12-21 | 2018-12-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54542A true MA54542A (fr) | 2021-10-27 |
Family
ID=69187971
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054542A MA54542A (fr) | 2018-12-21 | 2019-12-20 | Compositions de sparsentan amorphe |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20220048900A1 (fr) |
| EP (1) | EP3897834A1 (fr) |
| JP (1) | JP2022514569A (fr) |
| KR (1) | KR20210125994A (fr) |
| CN (1) | CN114126712A (fr) |
| AU (1) | AU2019404552A1 (fr) |
| BR (1) | BR112021012226A2 (fr) |
| CA (1) | CA3124127A1 (fr) |
| IL (1) | IL284186A (fr) |
| MA (1) | MA54542A (fr) |
| MX (1) | MX2021007258A (fr) |
| WO (1) | WO2020132594A1 (fr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102902972B1 (ko) | 2018-10-04 | 2025-12-22 | 트래버르 테라퓨틱스, 인코포레이티드 | Iv형 콜라겐 질환의 치료를 위한 비페닐 설폰아미드 화합물 |
| WO2022266370A1 (fr) | 2021-06-17 | 2022-12-22 | Aria Pharmaceuticals, Inc. | Sparsentan pour le traitement de la fibrose pulmonaire idiopathique |
| AR128112A1 (es) * | 2021-12-28 | 2024-03-27 | Alchemedicine Inc | Compuesto, antagonista del receptor de angiotensina ii tipo 1 y composición farmacéutica |
| JP2025183466A (ja) * | 2022-11-11 | 2025-12-17 | 株式会社アークメディスン | 化合物、エンドセリンa受容体拮抗剤、アンジオテンシンiiタイプ1受容体拮抗剤及び医薬組成物 |
| AU2024224496A1 (en) * | 2023-02-24 | 2025-10-02 | Changzhou Hansoh Pharmaceutical Co., Ltd. | Salt containing aromatic ring derivative antagonist, preparation method therefor, and application thereof |
| CN118666826A (zh) * | 2024-08-23 | 2024-09-20 | 成都臻拓医药科技有限公司 | 一种司帕生坦原料药的重结晶纯化方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6638937B2 (en) | 1998-07-06 | 2003-10-28 | Bristol-Myers Squibb Co. | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists |
| CA2395088A1 (fr) * | 1999-12-15 | 2001-06-21 | Bristol-Myers Squibb Company | Biphenyl sulfonamides utilises comme doubles antagonistes des recepteurs de l'angiotensine et de l'endotheline |
| JP2012522058A (ja) * | 2009-03-31 | 2012-09-20 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 血圧上昇および糖尿病性腎症を処置するための、ジフェニルスルホンアミドエンドセリンおよびアンジオテンシンii受容体アゴニストの経口製剤 |
| WO2010135350A2 (fr) * | 2009-05-20 | 2010-11-25 | Pharmacopeia, Llc | Composes intermediaires de biphenyle et procedes pour la preparation d'un double antagoniste de recepteur d'angiotensine ii et d'endotheline |
| KR20230066644A (ko) * | 2016-10-13 | 2023-05-16 | 트래비어 테라퓨틱스, 인코포레이티드 | 신장 질환 또는 장애의 치료를 위한 비페닐 설폰아미드 화합물 |
-
2019
- 2019-12-20 MA MA054542A patent/MA54542A/fr unknown
- 2019-12-20 MX MX2021007258A patent/MX2021007258A/es unknown
- 2019-12-20 CA CA3124127A patent/CA3124127A1/fr active Pending
- 2019-12-20 US US17/415,518 patent/US20220048900A1/en not_active Abandoned
- 2019-12-20 KR KR1020217021973A patent/KR20210125994A/ko not_active Ceased
- 2019-12-20 CN CN201980092448.1A patent/CN114126712A/zh active Pending
- 2019-12-20 AU AU2019404552A patent/AU2019404552A1/en not_active Abandoned
- 2019-12-20 EP EP19842514.2A patent/EP3897834A1/fr not_active Withdrawn
- 2019-12-20 BR BR112021012226-5A patent/BR112021012226A2/pt not_active IP Right Cessation
- 2019-12-20 JP JP2021535041A patent/JP2022514569A/ja active Pending
- 2019-12-20 WO PCT/US2019/068094 patent/WO2020132594A1/fr not_active Ceased
-
2021
- 2021-06-20 IL IL284186A patent/IL284186A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BR112021012226A2 (pt) | 2021-09-08 |
| MX2021007258A (es) | 2021-08-16 |
| JP2022514569A (ja) | 2022-02-14 |
| WO2020132594A1 (fr) | 2020-06-25 |
| EP3897834A1 (fr) | 2021-10-27 |
| IL284186A (en) | 2021-08-31 |
| CA3124127A1 (fr) | 2020-06-25 |
| AU2019404552A1 (en) | 2021-07-15 |
| US20220048900A1 (en) | 2022-02-17 |
| KR20210125994A (ko) | 2021-10-19 |
| CN114126712A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3722358A4 (fr) | Composition | |
| EP3644740A4 (fr) | Compositions agricoles | |
| DK3697376T3 (da) | Sammensætning | |
| EP3894163A4 (fr) | Compositions de revêtement | |
| DK3473674T3 (da) | Polypropylensammensætning | |
| MA50657A (fr) | Formulations de niraparib | |
| EP3823584A4 (fr) | Composition détergente | |
| DK3924443T3 (da) | Compositions | |
| EP3853332C0 (fr) | Composition | |
| EP3763805A4 (fr) | Composition de graisse | |
| EP3882323A4 (fr) | Composition | |
| EP3747978A4 (fr) | Composition de graisse | |
| MA54542A (fr) | Compositions de sparsentan amorphe | |
| EP3672944A4 (fr) | Compositions de nettoyage | |
| DK3840596T3 (da) | Sammensætning | |
| EP3871694A4 (fr) | Composition | |
| EP4234657C0 (fr) | Compositions | |
| EP3898809C0 (fr) | Composition de polypropylène | |
| EP3897866C0 (fr) | Composition antimicrobienne | |
| EP3981256A4 (fr) | Composition | |
| EP3941942A4 (fr) | Composition | |
| EP3999039A4 (fr) | Compositions de prétomanide | |
| DK3706724T3 (da) | Orale rifamycin-sv-sammensætninger | |
| MA50068A (fr) | Formulations de copanlisib | |
| EP3914303C0 (fr) | Composition virucide |